- PolyPeptide is expanding its Braine-l’Alleud site in Belgium, supported by customer financing.
- The investment includes advanced process equipment, strict environmental control capabilities, and a multi-year commercial contract.
PolyPeptide has announced a capacity expansion at its Braine-l’Alleud facility in Belgium. The investment, backed by customer financing, is aimed at strengthening its role in the growing global peptide market.
The upgrade will include advanced process equipment designed for complex peptides, along with strict environmental control systems to meet the requirements of demanding modalities. The expansion is also tied to a multi-year commercial contract, securing a long-term partnership with one of PolyPeptide’s clients.
“From early development to commercial supply, we’ve been in close collaboration with our client every step of the way. This investment demonstrates our strong partnership with our long-standing customer and our commitment to drive long-term growth.”
Stéphane Varray, Chief Commercial Officer at PolyPeptide
PolyPeptide highlighted that the expansion enhances its ability to provide end-to-end support, from development through to commercial supply.
The company stated the move reinforces its position as a CDMO partner for complex peptide therapeutics across global markets.
